Inhibitors of cyclic nucleotide phosphodiestrase PDE3 as adjunct therapy for dilated cardiomyopathy

Expert Opinion on Investigational Drugs

Volumn 11, Issue 11, 2002, Pages 1529-1536

  Movsesian, Matthew A ^a   Alharethi, Rami ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Cardiomyopathy; Cyclic AMP; Cyclic GMP; Cyclic nucleotide phosphodiesterases; Dilated; Heart failure; Inotropy; Myocardium

Indexed keywords

ADENYLATE CYCLASE; AMRINONE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; CARVEDILOL; CATECHOLAMINE; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYTOKINE; ENDOTHELIN; ENOXIMONE; ESMOLOL; FATTY ACID BINDING PROTEIN; HYDRALAZINE; LIGANDIN; METOPROLOL; MILRINONE; NITRATE; NORADRENALIN; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE; PLACEBO; PROTEIN X; RENIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; ENZYME INHIBITION; HEART DILATATION; HEART FAILURE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HUMAN; INOTROPISM; LONG TERM CARE; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOMYOPATHY, DILATED; HUMANS; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 0036850315     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.11.1529     Document Type: Review

References (67)

1. CONTI M, JIN SL: The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. (1999) 63:1-38.
2. SHAKUR Y, HOLST LS, LANDSTROM TR, MOVSESIAN MA, DEGERMAN E, MANGANIELLO V: Regulation and function of the cyclic nucleotide phosphodiesterase PDE3 gene family. Prog. Nucleic Acid Res. Mol. Biol. (2000) 66:241-277.
3. GHAZALEH FA, OMUBURO GA, COLMAN RW. Evidence for the presence of essential histidine and cysteine residues in platelet cGMP-inhibited phosphodiesterase. Biochem. J. (1996) 317:495-501.
4. ZHANG W, COLMAN RW: Conserved amino acids in metal-binding motifs of PDE3A are involved in substrate and inhibitor binding. Blood (2000) 95:3380-3386.
5. KURTZ A, GÖTZ KH, HAMANN M, WAGNER C: Stimulation of renin secretion by nitric oxide is mediated by phosphodiesterase 3. Proc. Natl. Acad. Sci. USA (1998) 95:4743-4747.
6. MOVSESIAN MA: Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cAMP. J. Am. Coll. Cardiol. (1999) 34:318-324.
7. SIMMERMAN HK, JONES LR: Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol. Rev. (1998) 78:921-947.
8. 2+ pump of the sarcoplasmic reticulum. Nature (1989) 342:90-92.
9. 2+-activated protease. J. Biol. Chem. (1984) 259:8550-8557.
10. TAKASAGO T, IMAGAWA T, SHIGEKAWA M: Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase. J. Biochem. (Tokyo) (1989) 106:872-877.
11. SCULPTOREANU A, ROTMAN E, TAKAHASHI M et al.: Voltage-dependent potentiation of the activity of cardiac L-type calcium channel alpha 1 subunits due to phosphorylation by cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA (1993) 90:10135-10139.
12. FRANCIS SH, NOBLETT BD,TODD BW, WELLS JN, CORBIN JD: Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. Mol. Pharmacol. (1988) 34:506-517.
13. LEROY MJ, DEGERMAN E, TAIRA M et al.: Characterization of two recombinant Type III cGMP-inhibited phosphodiesterase isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry (1996) 35:10194-10202.
14. JIANG H, COLBRAN JL, FRANCIS SH, CORBIN JD: Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J. Biol. Chem. (1992) 267:1015-1019.
15. m, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem. Biophys. Res. Comm. (1993) 190:516-521.
16. CHOI YH, EKHOLM D, KRALL J et al.: Identification of a novel isoform of PDE3A cyclic nucleotide phosphodiesterase in vascular smooth muscle myocytes. Biochem. J. (2001) 353:41-50.
17. WECHSLER J, CHOI YH, KRALL J, AHMAD F, MANGANIELLO VC, MOVSESIAN MA. Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J. Biol. Chem. (2002) 277:38072-38078.
18. LIU H, MAURICE DH: Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br. J. Pharmacol. (1998) 125:1501-1510.
19. BENOTTI JR, GROSSMAN W, BRAUNWALD E et al.: Hemodynamic assessment of amrinone. N. Engl. J. Med (1978) 299:1373-1377.
20. BAIM DS, MCDOWELL AV, CHERNILES J et al.: Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N. Engl. J. Med. (1983) 309:748-756.
21. SINOWAY LS, MASKIN CS, CHADWICK B et al.: Long-term therapy with a new cardiotonic agent, WIN 47203: Drug-dependent improvement in cardiac performance and progression of the underlying disease. J. Am. Coll. Cardiol. (1983) 2:327-331.
22. URETSKY BF, GENERALOVICH T, REDDY PS et al.: The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. Circulation (1983) 67:823-828.
23. JASKI BE, FIFER MA, WRIGHT RF et al.: Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. J. Clin. Invest. (1985) 75:643-649.
24. PACKER M, CARVER JR, RODEHEFFER RJ et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. (1991) 325:1468-1475.
25. FELDMAN AM, BRISTOW MR, PARMLEY WW et al.: Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N. Engl. J. Med. (1993) 329:149-155.
26. COHN JN, GOLDSTEIN SO, GREENBERG BH et al.: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N. Engl. J. Med. (1998) 339:1810-1816.
27. URETSKY BF, JESSUP M, KONSTAM MA et al.: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation (1990) 82:774-780.
28. NONY P, BOISSEL JP, LIEVRE M et al.: Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur. J. Clin. Pharmacol. (1994) 46:191-196.
29. LOWES BD, HIGGINBOTHAM M, PETROVICH L et al.: Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J. Am. Coll. Cardiol. (2000) 36:501-508.
30. LEE HR, HERSHBERGER RE, PORT ID et al.: Low dose enoximone in subjects awaiting cardiac transplantation clinical results and effect on beta adrenergic receptor. J. Thorac. Cardiovasc. Surg. (1991) 102:246-258.
31. ANONYMOUS: Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet (1990) 336:1-6.
32. OLIVA F, KRELL MJ, POLITI A et al.: Intermittent 6- months low dose dobutamine infusion in severe heart failure DICE Multicenter trial. Am. Heart J. (1999) 138:247-253.
33. O'CONNER CM, GATTIS WA, URETSKY BF et al.: Continuous intravenous dobutamine associated with an increase risk of death in patients with advanced heart failure: insight from the Flolan International Randomised Survival trial (FIRST) Am. Heart J. (2000) 138:78-86.
34. COHN JN, ARCHIBALD DG, ZIESCHE S et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. (1986) 314:1547-1552.
35. CUFFE MS, CALIFF RM, ADAMS KF Jr et al.: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomised controlled trial. The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. JAMA (2002) 287:1541-1547.
36. PACKER M, BRISTOW MR, COHN JN et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl. J. Med. (1996) 334:1349-1355.
37. PACKER M, COLUCCI WS, SACKNER-BERNSTEIN JD et al.: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomised Evaluation of Carvedilol on Symptoms and Exercise. Circulation (1996) 94:2793-2799.
38. BRISTOW MR, GILBERT EM, ABRAHAM WT et al.: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation (1996) 94:2807-2816.
39. HJALMARSON A, GOLDSTEIN S, FAGERBERG B et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomised Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA (2000) 283:1295-1302.
40. PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344:1651-1858.
41. GOLDSTEIN S, FAGERBERG B, HJALMARSON A et al.: Metoprolol controlled release/extended release in patients with severe heart failure. Analysis of the experience in the MERIT-HF study. J. Am. Coll. Cardiol. (2001) 38:932-938.
42. BRISTOW MR, GILBERT EM, OLSEN S et al.: Long-term metoprolol therapy increases myocardial beta-adrenergic receptor density relative to placebo controls. J. Am. Coll. Cardiol. (1993) 21:101A.
43. EICHHORN EJ, MCGHIE AL, BEDOTTO JB et al.: Effects of bucindolol on neurohormonal activation in congestive heart failure. Am. J. Cardiol. (1991) 67:67-73.
44. YOSHIKAWA T, HANDA S, ANZAI T et al.: Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. Am. Heart J. (1996) 131:329-336.
45. KRUM H, GU A, WILSHIRE-CLEMENT M et al.: Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am. Heart J. (1996) 131:337-341.
46. KIM MH, DEVLIN WH, DAS SK et al.: Effects of beta-adrenergic blocking therapy on left ventricular diastolic relaxation properties in patients with dilated cardiomyopathy. Circulation (1999) 100:729-735.
47. GROENNING BA, NILSSON JC, SONDERGAARD L et al.: Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J. Am. Coll. Cardiol. (2000) 36:2072-2080.
48. LOWES BD, GILL EA, ABRAHAM WT et al.: Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am. J. Cardiol. (1999) 83:1201-1205.
49. OHTSUKA T, HAMADA M, HIASA G et al.: Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. (2001) 37:412-417.
50. PRABHU SD, CHANDRASEKAR B, MURRAY D, FREEMAN GL: beta-adrenergic blockade in developing heart failure, effects on myocardial inflammatory cytokines, nitric oxide, and remodelling. Circulation (2000) 101:2103-2109.
51. CICE G, TAGLIAMONTE E, FERRARA L, IACONO A: Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomised, placebo-controlled study. Eur. Heart J. (2000) 21:1259-1264.
52. MACDONALD PS, KEOGH AM, ABOYOUN CL, LUND M, AMOR R, MCCAFFREY DJ: Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J. Am. Coll. Cardiol. (1999) 31:924-931.
53. AUSTRALIA-NEW ZEALAND HEART FAILURE RESEARCH COLLABORATIVE GROUP: Randomised placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet (1997) 349:375-380.
54. SHAKAR SF, ABRAHAM WT, GILBERT EM et al.: Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J. Am. Coll. Cardiol. (1998) 31:1336-1340.
55. KUMAR A, CHOUDHARY G, ANTONIO C et al.: Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am. Heart J. (2001) 142:512-515.
56. HAUPTMAN PJ, WOODS D, PRITZKER MR: Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. Clin. Cardiol. (2002) 25:247-249.
57. YOSHIKAWA T, BABA A, SUZUKI M et al.: Effectiveness of carvedilol alone versus carvedilol+pimobendan for severe congestive heart failure. Am. J. Cardiol. (2000) 85:1495-1497.
58. 1. J. Biol. Chem. (1980) 255:5113-5119.
59. 2+ current in single rat ventricular cells. Circ. Res. (1993) 73:286-300.
60. 2+ dynamics, contractility, or phospholamban phosphorylation. J. Biol. Chem. (1994) 269:19151-19156.
61. RYBIN VO, XU X, LISANTI MP, STEINBERG SF: Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signalling pathway. J. Biol. Chem. (2000) 275:41447-41457.
62. RAPUNDALO ST, SOLARO RJ, KRANIAS EG: Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. Circ. Res. (1989) 64:104-111.
63. 2+ channels by beta-adrenergic agonists. Proc. Natl. Acad. Sci. USA (1996) 93:295-299.
64. 2+ channel pathways. J. Clin. Invest. (1999) 103:1089-1097.
65. 2+ channels: preferential coupling of the beta1 versus beta2 receptor subtype and evidence for PKA-independent activation of the channel. Cell. Signal. (1999) 11:337-342.
66. YARBROUGH TL, LU T, LEE HC, SHIBATA EF: Localization of cardiac sodium channels in caveolin-rich membrane domains: regulation of sodium current amplitude. Cirr. Res. (2002) 90:443-449.
67. SCHAFER M, FRISCHKOPF K, TAIMOR G, PIPER HM, SCHLUTER KD: Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. Am. J. Physiol. Cell Physiol. (2000) 279:C495-C503.